In this episode, I explore Nvidia's significant investment of $50 million in Recursion, highlighting its impact on revolutionizing drug discovery by leveraging AI technologies.
 
<ul>
 <li>Invest in AI Box: <a href="https://republic.com/ai-box">https://Republic.com/ai-box</a></li>
 <li>Get on the AI Box Waitlist: <a href="https://aibox.ai/">https://AIBox.ai/</a></li>
 <li><a href="https://www.facebook.com/groups/739308654562189">AI Facebook Community</a></li>
</ul>

In this episode, I explore Nvidia's significant investment of $50 million in Recursion, highlighting its impact on revolutionizing drug discovery by leveraging AI technologies. Invest in AI Box: https://Republic.com/ai-box Get on the AI Box Waitlist: https://AIBox.ai/ AI Facebook Community

In this episode, I explore Nvidia's significant investment of $50 million in Recursion, highlighting its impact on revolutionizing drug discovery by leveraging AI technologies.
 
<ul>
 <li>Invest in AI Box: <a href="https://republic.com/ai-box" rel="noopener noreferrer">https://Republic.com/ai-box</a></li>
 <li>Get on the AI Box Waitlist: <a href="https://aibox.ai/" rel="noopener noreferrer">https://AIBox.ai/</a></li>
 <li><a href="https://www.facebook.com/groups/739308654562189" rel="noopener noreferrer">AI Facebook Community</a></li>
</ul>

Nvidia's $50M Bet: Transforming Drug Discovery with Recursion's AI

"Serial AI" is a cutting-edge podcast dedicated to exploring the ever-evolving world of artificial intelligence and technology. Each episode delves into the latest trends, developments, and breakthroughs in AI, offering listeners insightful and comprehensive coverage of this dynamic field. With a focus on how these advancements are shaping our future, the podcast presents a balanced mix of detailed analyses, industry news, and potential implications of AI in various sectors.

Share Nvidia's $50M Bet: Transforming Drug Discovery with Recursion's AI

Sign up to save your podcasts

Nvidia's $50M Bet: Transforming Drug Discovery with Recursion's AI

Nvidia's $50M Bet: Transforming Drug Discovery with Recursion's AI